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SERUM OMENTIN AS A POTENTIAL BIOMARKER FOR COMPLEX ATYPICAL 
HYPERPLASIA AND ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA 
 
Laura L. Holman, M.D. 
Supervisory Professor:  Karen H. Lu, M.D. 
Abstract 
Obesity is a significant risk factor for endometrial cancer, the most common gynecologic 
malignancy in the United States, but much remains unclear about the relationship between 
obesity-related factors and the development of endometrial cancer.  Omentin, a recently 
discovered adipokine, has been shown to be present in lower levels in patients who are 
obese and/or insulin resistant. A case-control study was conducted using the serum of 140 
women with endometrial cancer and 75 women with endometrial hyperplasia who were 
matched 1:1 based on body mass index (BMI) and menopausal status to women with no 
history of endometrial cancer (controls). The concentration of omentin in the patients’ serum 
was experimentally determined by conducting tests in triplicate on an enzyme-linked 
immunoadsorbent assay (ELISA) specific to human omentin. The mean serum omentin 
levels of women with endometrial hyperplasia and endometrial cancer were statistically 
significantly lower than controls, regardless of BMI.  The mechanism that induces this 
change remains unknown, but these results present exciting promise for omentin’s use as a 
biomarker and role in understanding the relationship between obesity-related factors and 
endometrial carcinoma.    
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Background and Introduction 
Endometrial Adenocarcinoma 
 Endometrial cancer is a malignant process that arises from the inner lining 
of the uterus (endometrium).  It is the fourth most common cancer among women 
in the United States and the most frequently diagnosed gynecologic malignancy.  
In 2014, more than 52,000 American women will be diagnosed with the 
disease.[1] 
 Endometrial cancer is most commonly diagnosed in postmenopausal 
women, with a median age at diagnosis of 62 years.  While white women are 
most likely to develop the disease compared to other races, black women are 
most likely to die from the disease (Table 1).[2]  Reasons for this disparity are 
unclear. 
 
Race New Cases Deaths 
White 25.4 4.0 
Black 23.2 7.5 
Asian 19.1 2.7 
Native American 20.0 3.4 
Hispanic 19.8 3.4 
Table 1: Endometrial Cancer Cases and Deaths per 100,000  
  People[2]. Number of cases and deaths by race in 2014. 
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 Histologically, endometrial cancer is classically divided into two 
categories:  type I and type II.  Type I tumors account for up to 85% of 
endometrial cancers and are defined as grade 1 or grade 2 endometrioid 
endometrial cancers.  Most of these tumors are diagnosed at an early stage and 
therefore confer a favorable prognosis.  Of interest, type I endometrial cancers 
are estrogen-dependent and often develop in the setting of complex atypical 
hyperplasia of the endometrium.  Aberrations in PTEN and K-ras are commonly 
found in type I tumors.[3]  In contrast, type II endometrial cancers are high grade 
and are more likely to be diagnosed at an advanced stage.  They have no known 
precursor lesion.  As such, type II endometrial cancer often has a poor prognosis.  
Mutations in p53 are frequently identified in these tumors.[4] 
The strongest risk factor for type I endometrial cancer is unopposed 
estrogen therapy, with a relative risk of 10-20.  While unopposed estrogen may 
be due to exogenous estrogen, such as hormone replacement therapy or 
tamoxifen, it is more commonly due to excess endogenous estrogen.  Several 
factors can increase endogenous estrogen, including chronic anovulation (such 
as in patients with polycystic ovarian syndrome or PCOS), an estrogen-producing 
tumor, or obesity.  Of these, however, obesity confers the greatest risk.[5]  
Studies have found that obesity confers up to a five-fold risk of developing 
endometrial cancer when compared to normal-weight women.[6]  Other risk 
factors for type I tumors include advanced age, diabetes, and hypertension, and 
some genetic syndromes, such as Lynch Syndrome.  The risk factors for type II 
tumors are not well understood. 
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Early stage endometrial cancer is highly curable, with 5-year survival rates 
approaching 90% for patients with stage I malignancies.[7]  In fact, many women 
with early stage, grade 1 or 2, endometrioid, endometrial cancer will be cured 
with surgical resection alone.  However, the majority of patients who recur are 
incurable, with an average survival of only six to eighteen months.[8]   
There are currently no prognostic biomarkers for endometrial cancer 
consistently utilized in clinical practice.  However, multiple markers have been 
associated with prognosis in studies.  For example, expression of EGFR in 
endometrioid tumors has been found to predict a decrease in survival by up to 
20% from patients without EGFR expression.[9]  Other potential markers of poor 
prognosis include p53 overexpression, DNA methylation, and increased Ki-67 
staining.  Expression of estrogen and progesterone receptors has been 
associated with improved prognosis.[10] 
Endometrial Hyperplasia 
Endometrial hyperplasia is a benign overgrowth, or proliferation, of glands 
in the endometrium.  It is also most commonly diagnosed in postmenopausal 
women.  As the precursor lesion to type I endometrial cancers, it has similar risk 
factors with obesity as the most significant risk factor. 
In an attempt to classify hyperplasia, the World Health Organization 
(WHO) has divided endometrial hyperplasia into four categories based upon the 
glandular and stromal pattern of the endometrium and the presence or absence 
of nuclear atypia.  These four categories are simple hyperplasia without atypia, 
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complex hyperplasia without atypia, simple hyperplasia with atypia, and complex 
hyperplasia with atypia.[11]  Though all patients with endometrial hyperplasia 
have a risk of developing endometrial cancer, some histologic subtypes have a 
greater risk than others.  The WHO classification system correlates well with this 
risk (Table 2).[12] 
WHO Classification Incidence of Endometrial Cancer 
Simple Hyperplasia without Atypia 1% 
Simple Hyperplasia with Atypia 3% 
Complex Hyperplasia without Atypia 8% 
Complex Hyperplasia with Atypia 29% 
  Table 2: Incidence of Endometrial Cancer by WHO Hyperplasia  
  Category[12].  Categories of hyperplasia ranked by risk of endometrial  
  cancer development. 
 Of all subtypes of endometrial hyperplasia, complex atypical hyperplasia 
confers the greatest risk of developing cancer.  Prior observational studies have 
noted that it takes several years for women who have complex atypical 
hyperplasia to develop cancer.[13]  However, up to 35% of women with complex 
atypical hyperplasia will have an underlying malignancy in their hysterectomy 
specimen.[14]  For this reason, the definitive treatment for complex hyperplasia 
with atypia is hysterectomy. 
 As the risk for developing endometrial cancer in women with hyperplasia 
without atypia is low, it can be managed with progestin therapy.  This may 
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include oral progesterone or progesterone-impregnated intrauterine devices 
(IUD).  Studies have noted regression of hyperplasia without atypia in up to 80% 
of women treated with oral progesterone.[15, 16]  Of interest, studies have noted 
an increased rate of regression of complex hyperplasia without atypia in women 
who utilize the IUD than in women treated with oral progesterone.  However, 
there was no significant difference in the rate of regression among women with 
simple hyperplasia without atypia.[17]   Figure 1 illustrates the difference 
between benign endometrium, endometrial hyperplasia, and endometrial 
adenocarcinoma under low power. 
A     B 
 
 
 
 
 
 
 
 
                     
 
             C 
 
 
 
 
 
 
Figure 1:  H&E Comparing Normal Endometrium to Hyperplasia and  
Cancer.  A) Proliferative endometrium.  B) Complex atypical hyperplasia.  
C) Endometrial Adenocarcinoma 
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Obesity and Development of Endometrial Hyperplasia and Cancer 
 Obesity is one of the greatest risk factors for developing endometrial 
hyperplasia or cancer.  In fact, almost 50% of endometrial cancer cases may be 
related to obesity.[18]  Furthermore, increasing body mass index (BMI) leads to 
increased risk.  Lu and colleagues demonstrated that overweight women were 
twice as likely and obese women up to five times as likely to develop endometrial 
cancer as their normal-weight counterparts.[6]  In fact, for each 5 kg/m2 increase 
in BMI, there is a significant increase in risk of developing endometrial 
cancer.[19] 
 In addition to being at increased risk for developing endometrial cancer, 
obese women are at increased risk for dying from the disease.  Calle and 
colleagues found that obese women were approximately 2.5 times more likely 
and morbidly obese women were 6 times more likely than normal-weight women 
to die from endometrial cancer.[20]  Additionally, obese endometrial cancer 
patients are almost 3 times as likely to die from causes other than endometrial 
cancer.[21]  This is likely secondary to the association of obesity with other 
medical conditions, such as diabetes mellitus, hypertension, and cardiac disease. 
The Role of Estrogen in the Development of Endometrial Cancer 
Unopposed estrogen, whether exogenous or endogenous, is a well-known 
risk factor for the development of endometrial hyperplasia and cancer.  In the 
1960’s, the first cases of endometrial cancer related to hormone replacement 
therapy were reported.[22]  This observation has been validated in multiple 
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studies since that time.[23-25]  Furthermore, the cancer risk has been found to 
be associated with both dose and duration of estrogen use.[26, 27] 
It has long been hypothesized that unopposed endogenous or exogenous 
estrogen leads to the development of endometrial cancer.  Though 
premenpausal women make estrogen mostly in the ovaries, postmenopausal 
women form estrogen only in peripheral tissue, including adipose tissue.  In 
adipose tissue, aromatase converts androgens to estrone and estradiol (Figure 
2).  Aromatase is an enzyme produced in the adipose tissue and levels are 
increased in obesity.  The increased aromatase levels in combination with 
decreased sex hormone binding globulin levels lead to increased circulating 
estrogen levels in obese women.  In fact, studies have demonstrated up to 40% 
higher estrogen levels in obese as compared with normal-weight 
postmenopausal women.[28]   Furthermore, studies have shown an association 
between elevated estrogen concentration and endometrial cancer.[29, 30] 
 The mechanism by which excess unopposed estrogen leads to 
endometrial hyperplasia and cancer is complex.  In essence, however, estrogen 
leads to increased mitotic activity in endometrial cells.  This can cause DNA 
replication errors and eventually mutations that result in the development of  
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carcinoma.[31, 32]  Estrogen is also involved in activation of kinase signaling                      
  Figure 2:  Conversion of Androgens to Estrogens in Adipose Tissue. 
Mechanism by which testosterones are converted to estrogens by the   
  enzyme aromatase in peripheral tissue. 
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cascades, including the PI3 and MAP kinase pathways, via association between 
estrogen receptors and cell surface receptors.[33]  These pathways lead to 
cellular proliferation and aberrations in them are frequently found in endometrial 
cancer.[34]  
A model for the role of estrogen in the pathogenesis of endometrial cancer 
has been proposed by Rizner in 2013.[35]  In this hypothesis, estrogens are 
synthesized in peripheral tissue (mainly adipose tissue), leading to increased 
circulating levels of estrogens.  These estrogens are transported into the 
endometrial cells, where they are metabolized into 4-hydroxyestrogens and 3,4-
quinones due to upregulation of the enzyme CYP1B1.  The 3,4-quinones 
produced by this reaction induce formation of DNA adducts and reactive oxygen 
species, which can cause mutations in tumor suppressor genes or oncogenes, 
such as PTEN and K-RAS.  These mutations lead to the development of cancer.  
In these cancer cells, estrogen receptor is over-expressed (specifically, estrogen 
receptor α), leading to more estrogen binding and proliferation of the mutated 
cells.  Of note, the Dr. Rizner is careful to point out that this hypothesis is based 
on interpretation of the available literature and that further studies are warranted 
to fully evaluate its accuracy. 
Insulin Resistance and the Development of Endometrial Cancer 
While the prevailing hypothesis is that unopposed estrogen is the driver of 
endometrial cancer development, there is increasing evidence that insulin 
resistance may also play a role.  Insulin resistance is decreased sensitivity to 
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insulin leading to increased blood glucose levels.[36]  Patients with insulin 
resistance develop hyperinsulinemia to compensate for the hyperglycemic state.  
This increased insulin concentration has been correlated with the development of 
malignancies, including endometrial cancer.  Several studies have associated 
insulin resistance with endometrial cancer, even when controlling for obesity or 
estrogen levels.[37-39] 
Inflammatory mediators are believed to be some of the common 
regulatory factors in both insulin resistance and the development of endometrial 
cancer.  In insulin resistance, inflammation recruits of macrophages to adipose 
tissue via secretion of monocyte chemoattractant protein-1.  By releasing tumor 
necrosis factor-α, the macrophages activate the extracellular signal-related 
kinase and c-Jun-N-terminal-kinase pathways, thereby inhibiting insulin signaling.  
The macrophages also secrete interleukin-6, which is believed to play a role in 
insulin resistance, though the exact mechanism is unknown.[36, 40-42]  
Interleukin-6 is also known to lead to secretion of C-reactive protein, which is a 
marker of inflammation and has been associated with endometrial cancer 
risk.[43] 
The hyperinsulinemia associated with insulin resistance has been 
associated with the development of endometrial cancer.  For example, in vitro, 
endometrial cancer cell lines treated with insulin lead to decreased apoptosis and 
increased cellular proliferation in a dose-dependent fashion.  This finding is likely 
secondary to activation of insulin receptor upon insulin binding, leading to 
activation of the PI3K and MAPK pathways.[36, 44]  The activated PI3K and 
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MAPK pathways can subsequently activate estrogen receptor, thereby leading to 
unregulated cell growth and division.[45]  In fact, these pathways have been 
associated with a large percentage of endometrial cancers.[46]   
Hyperinsulinemia may also lead to endometrial cancer development 
through indirect mechanisms.  For example, insulin inhibits production of sex 
hormone binding globulin, thereby causing increased blood levels of free sex 
hormones, such as estrogens and androgens.[47]  Furthermore, insulin promotes 
androgen production by the ovaries.  This allows for more free androgen to be 
converted to estrogen in the peripheral tissues. 
Insulin resistance can be difficult to study as there are many different 
methods to measure it.  These approaches include the QUICKI (1/[log fasting 
insulin + log fasting glucose]), the insulin resistance index (fasting plasma 
glucose x fasting insulin / 25), and the HOMA-IR index (fasting insulin x fasting 
glucose / 22.5).[37-39]  Unfortunately, there is no standard method to measure 
insulin resistance and no universally accepted way to measure the relationship 
between insulin resistance and endometrial cancer. 
Given the association between insulin resistance and endometrial cancer, 
there has been increasing interest in insulin-sensitizing agents as potential 
therapies for endometrial cancer.  Metformin is one of the agents that is being 
investigated for this purpose.  In vivo, metformin has been found to inhibit 
endometrial cancer cell growth through mTOR inhibition and AMPK 
activation.[48]  Other in vivo and in vitro studies have found that metformin may 
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have the greatest effect in cells with K-Ras mutations.[49]  Recently, a phase II 
trial of everolimus and letrozole in patients with recurrent endometrial cancer 
found a significantly higher response rate in patients who were also taking 
metformin.[50]  This unexpected finding led to the development of a phase II trial 
of everolimus, letrozole, and metformin among women with recurrent endometrial 
cancer, which is currently accruing patients (ClinicalTrials.gov identifier:  
NCT01797523). 
Adipokines 
 Historically, adipose tissue has been thought of as only insulation and a 
storage site for energy.  However, it is now known that adipose tissue is also an  
endocrine organ that is involved in bone remodeling, immunity, and energy 
homeostasis.[51]  Adipose tissue also secretes a class of cytokines called 
adipokines.  Multiple adipokines with varied functions that can act either locally or 
systemically have been described (Table 3). 
 Adipokines have been associated with the development and progression 
of multiple cancers, including breast, colon, pancreas, and endometrial.[52]  This 
is believed to occur through the activity of pro-inflammatory adipokines, which 
stimulate cancer stem cells.  This produces a feedback loop whereby there is 
increased secretion of pro-inflammatory adipokines leading to tumor growth.[53]  
Alternatively, some adipokines have been proposed as protective against cancer 
development with decreased serum levels in patients with cancer.  
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Adipokine Proposed Function(s) 
Adiponectin Increases insulin sensitivity, Anti-inflammatory 
Adipsin Activates alternative complement pathway 
Angiotensin II Regulation of blood pressure 
Apelin Aid in control of energy stores 
Appetite-Regulating Hormone Aid in distribution and rate of energy use 
Complement C1q TNF-Related 
Protein 1 
Increases insulin sensitivity, Anti-inflammatory 
Chemerin 
Aids with adipocyte differentiation and glucose 
uptake 
IL-6 Proinflammatory, Multiple functions 
IL-8 Proinflammatory, Multiple functions 
Leptin Signals CNS regarding energy stores 
Lipocalin 2 Promotes insulin resistance 
Monocyte Chemoattractant 
Protein 1 
Proinflammatory, Promotes insulin resistance 
Omentin Anti-inflammatory 
Plasminogen Activator Inhibitor 
1 
Inhibits plasminogen activation 
Resistin Increases insulin resistance 
TNF-α 
Reduces insulin sensitivity, Increases energy 
consumption 
Vaspin Increases insulin sensitivity 
Visfatin Increases insulin sensitivity 
Table 3:  Select Adipokines and Proposed Functions [52, 54].  Selection of 
some of the most commonly studied adipokines with their proposed function. 
  Adioponectin, an adipokine produced exclusively by adipocytes, has been 
associated with insulin resistance and in the pathogenesis of endometrial cancer.  
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For example, in insulin resistance pathways, adiponectin has been noted to 
activate AMP-activated protein kinase and peroxisome proliferator-activated 
receptor-α.  These enzymes decrease serum glucose concentration and increase 
the expression of adiponectin and adiponectin receptors, leading to a positive 
feedback loop.[36, 55]  Interestingly, serum adiponectin levels have been 
inversely correlated with insulin levels.[56, 57]  Serum adiponectin levels have 
also been found to be lower in endometrial cancer patients than in women with 
endometrial hyperplasia or normal endometrium.[58]  Other studies have 
confirmed that adiponectin levels are decreased in endometrial cancer patients 
as compared with controls and that elevated adiponectin levels are associated 
with a lower risk of endometrial cancer.[59-61]  Of note, adiponectin receptors 
are expressed in both benign and malignant endometrial cancer cell lines, but 
treatment with adiponectin in the malignant cell lines led to apoptosis.[62, 63]  
This suggests a possible therapeutic application for adiponectin, but further 
studies are needed. 
Insulin resistance also appears to be mediated by leptin.  This adipokine 
inhibits insulin receptor and promotes the activity of other proteins that have been 
associated with insulin resistance.[64, 65]  The leptin receptor is also expressed 
on multiple endometrial cancer cell lines and leptin may lead to increased 
proliferation and invasion of these cells.[66, 67]  The prognostic implications of 
leptin are unclear as findings from clinical studies have been contradictory.  
Small studies of serum leptin levels have found no difference between 
endometrial cancer patients and controls.[68]  However, a meta-analysis that 
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included approximately 3,000 patients found elevated serum leptin to be an 
independent risk factor for endometrial cancer.[69] 
Omentin 
 Omentin, also known as intelectin, is a recently discovered adipokine that 
is expressed by multiple tissues, including the heart, lungs, and ovary.[70]  
However, omentin is preferentially secreted by the mesothelial cells of visceral 
adipose tissue.  There are two isoforms of omentin:  omentin-1 and omentin-2.  
However, omentin-1 is the major circulating isoform in human plasma.  Omentin 
is believed to be an insulin-sensitizing adipokine and aids with glucose uptake in 
adipocytes as well as AKT signaling.[71]   
 It has been hypothesized that omentin has a role as an anti-inflammatory 
agent since levels are generally decreased in patients with pro-inflammatory 
conditions (Figure 3).  For example, serum omentin levels are decreased among 
patients with inflammatory bowel disease.[72]  Furthermore, there is some 
evidence that decreased omentin levels may correlate with disease activity in 
these patients.[73]   Li and colleagues recently demonstrated that omentin levels 
in synovial fluid of osteoarthritis patients are negatively correlated to disease 
severity.[74]  Type 1 and type 2 diabetes mellitus are also associated with 
decreased plasma omentin levels.[75, 76]  This negative correlation remains true 
when controlling for BMI.[76]  Furthermore, treating omental adipose tissue with 
insulin and glucose dose-dependently decreases omentin expression in this 
tissue.[75] 
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Figure 3:  Omentin in Other Disease Processes.  Many pro- 
inflammatory diseases have found an inverse correlation with omentin, 
including obesity, diabetes, arthritis, PCOS, and inflammatory bowel 
syndrome. 
Arthritis 
- Serum and synovial fluid 
omentin  
  decreased 
- Levels inversely correlated 
with radiographic severity of 
disease 
Coronary Artery Disease 
- Omentin levels decreased 
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PCOS 
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    insulin resistance 
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may contribute to decreased 
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worsening insulin resistance 
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Omentin levels have also been inversely correlated to BMI, waist 
circumference, and other markers of obesity.[77]  Interestingly, omentin levels 
have been noted to increase with weight loss and aerobic exercise.[78, 79]  Tan 
and colleagues also demonstrated an increase in serum omentin levels after 
treatment with metformin in women with polycystic ovarian syndrome 
(PCOS).[80]  However, this has not been evaluated in obesity. 
The mechanism of omentin’s anti-inflammatory function is poorly 
understood, though there is evidence that it may be via activation of AMPK and 
inhibition of TNF-α.  For example, Yamawaki and colleagues demonstrated that 
omentin inhibits TNF-α-induced COX-2 expression in vascular endothelial cells.  
It has been hypothesized that omentin is able to do this by inhibiting JNK via 
activation of the AMPK/eNOS/NO pathway.[81, 82]   
Omentin and Cancer 
 Cancer is also an inflammatory disease state, but few studies have 
attempted to examine the relationship between omentin and cancer.  In their 
study of tissue from 196 patients with gastric cancer, Zheng and colleagues 
found that more than 72% of tumors expressed intelectin (omentin).  Additionally, 
intelectin positivity of these tumors was inversely correlated with depth of 
invasion, lymph node metastases, distant metastases, and clinical stage.[83]  
Omentin levels were also noted to be decreased in patients with colorectal 
cancer and the findings of one small study suggested that omentin may be able 
to aid with prognosis in advanced stage colorectal cancer patients.[84, 85]  
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Furthermore, omentin levels appear to be elevated after these patients complete 
their therapy as compared with healthy controls.[86]  Of interest, a recent study 
of prostate cancer patients found that they had higher omentin levels than 
patients with benign prostate disease.  However, BMI and other confounders 
were not controlled for and these results have not yet been validated.[87]  
Unpublished work from our lab has noted that circulating omentin levels are 
lower in women with ovarian cancer and higher levels have been correlated with 
improved overall survival.  These findings provide exciting promise for the use of 
omentin as a potential prognostic biomarker in malignancies. 
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Hypotheses and Specific Aims 
 There are currently no studies evaluating omentin in endometrial 
hyperplasia or endometrial cancer.  Given that these are both inflammatory 
states associated with obesity and insulin resistance, it would be prudent to study 
the role of omentin in this disease process.   
The present study was intended to better understand the relationship 
between omentin and endometrial hyperplasia and endometrial cancer with the 
following specific aims: 
 
• Specific Aim 1:  To evaluate the serum omentin levels of women 
with complex atypical hyperplasia of the endometrium and 
endometrioid endometrial adenocarcinoma as compared with 
controls. 
o Hypothesis:  Serum omentin levels will be decreased in 
women with complex atypical hyperplasia of the 
endometrium or endometrial adenocarcinoma, independent 
of BMI or menopausal status. 
 
• Specific Aim 2:  To assess the difference in serum omentin levels 
among BMI groups in women with complex atypical hyperplasia of 
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the endometrium and endometrioid endometrial adenocarcinoma 
as compared with controls. 
o Hypothesis:  Serum omentin levels will be lower among 
obese women with complex atypical hyperplasia of the 
endometrium or endometrial adenocarcinoma as compared 
with normal-weight women with these diseases. 
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Methods 
Approvals 
 Approval for relevant studies was obtained from the University of Texas at 
MD Anderson Cancer Center Institutional Review Board (IRB). 
Statistical Considerations 
Clinical characteristics and demographics were summarized with descriptive 
statistics.  Because this was a matched case-control study and data were paired, 
the paired difference in omentin was measured between cancer cases and their 
controls.  Descriptive statistics were then utilized to summarize these differences.  
A t-test was performed on the differences from zero within each BMI category.  
The Wilcoxon rank sum test was then used to compare BMI groups with respect 
to medians of these differences.  A similar analysis was performed on the paired 
difference in omentin between hyperplasia cases and controls.  A p-value of 
<0.05 was considered statistically significant.   
Clinical Analysis 
 A retrospective, laboratory-based case-control study was conducted to 
compare the levels of omentin in women with endometrial adenocarcinoma or 
endometrial hyperplasia (cases) to women with no history of cancer (controls).  
After IRB approval was obtained, cases and controls were identified in the 
University of Texas MD Anderson gynecologic oncology tumor bank.  All women 
with samples stored in the tumor bank provided informed consent to have their 
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blood, urine, and tissue samples collected at the time of surgery and be stored 
for future research.  
 To be included in the study, cases must have a confirmed diagnosis of 
grade 1 endometrioid endometrial adenocarcinoma or complex atypical 
hyperplasia with serum available in the tumor bank.  Patients with type II tumors, 
inadequate banked serum, or without available data in the clinical record were 
excluded from the study.  Women included in the control group must have no 
history of endometrial hyperplasia or carcinoma with serum available in the tumor 
bank.  Additionally, controls were matched to the cases with respect to 
menopausal status and BMI category (Table 4).  Patients were excluded from the 
control group if they had active cancer of any kind at the time of serum collection, 
inadequate banked serum, or no available data in the clinical record.   
Category BMI Range (kg/m2) 
Underweight < 18.5 
Normal Weight 18.5 – 25 
Overweight 26 – 30 
Obese >30 
Table 4:  BMI Categories.  Standarized classification of BMI. 
In total 140 cancer cases and 72 hyperplasia cases were matched 1:1 to 
controls by BMI and menopausal status.  Clinical data for both cases and 
controls was then obtained from the medical record, including age, ethnicity, 
menopausal status, medical history, and pathology. 
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ELISA 
Patient serum samples were initially obtained from centrifuged whole 
blood and stored in a freezer at -800 Celsius before being thawed for the purpose 
of this study.  Serum omentin was measured in using a commercially available 
enzyme-linked immunoadsorbent assay (ELISA) kit (BioVendor, Human 
Omentin-1 ELISA, Czech Republic).  The assay was performed in triplicate for 
each sample and the mean concentration of omentin for each patient 
determined. 
Prior to beginning the assay, serum samples were diluted 1:40 using a 
dilution buffer provided in the kit.  The standards were prepared according to the 
kit instructions to obtain omentin concentrations of 64 ng/mL, 32 ng/mL, 16 
ng/mL, 8 ng/mL, 4 ng/mL, and 2 ng/mL.  Quality controls were also prepared with 
dilution buffer and assayed to ensure that the results were acceptable.  All 
samples, standards, and quality controls were mixed with a vortex prior to 
pipetting 100 µL of each into a 96-well plate.  
After all samples were plated, the plate was incubated at 370 Celsius for 
two hours without shaking.  The wells were then removed from the incubator, 
aspirated, and washed with 300 µL of wash solution (provided by the kit) three 
times.  After this wash, 100 µL of a biotin-labeled antibody solution (provided by 
the kit) was pipetted into each well.  The plate was then incubated at 370 Celsius 
for 30 minutes without shaking.  The plate was again removed from the 
incubator, aspirated, and washed three times with 300 µL of wash solution.  Next, 
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100 µL of streptavidin-HRP conjugate was pipetted into each well.  The plate was 
again incubated without shaking at 370 Celsius for 30 minutes.  Upon removal 
from the incubator, the plate was aspirated and washed three times with 300 µL 
of wash solution.  After completion of this wash, 100 µL of substrate solution was 
added to each well.  The plate was covered with aluminum foil and incubated at 
room temperature for 10 minutes.  After the incubation period, 100 µL of stop 
solution was added to halt the color change.   
Upon completion of the ELISA, the plate was read by a microplate reader 
set to 450 nm with a reference wavelength of 630 nm.  A standard curve was 
calculated by subtracting the absorbance values for the wavelengths, plotting the 
difference of absorbencies on the y-axis against the known concentration of the 
standards on the x-axis.  The x-axis was then set to a logarithmic scale.  The 
omentin concentration of the samples was obtained using the standard curve and 
multiplying values by 40 to adjust for the dilution of the sample.   
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Results 
 As demonstrated in table 5, cancer cases, hyperplasia cases, and controls 
had similar demographic and clinical factors.  Overall, almost three-fourths of 
women were white, and this proportion was similar between groups.  The mean 
age was 58, though women in the hyperplasia group were slightly younger.  The 
BMI of each group was very similar, as expected given that the groups were 
matched based upon BMI. 
Characteristic Cancer Hyperplasia Controls Total 
Mean Age (SD) 60 (±11.44) 53 (±12.29) 59 (±11.62) 58 (±11.62) 
Ethnicity (n) 
  White  
  Black  
  Hispanic  
  Asian  
 
68.6 (96) 
4.3 (6) 
20 (28) 
7.1 (10) 
 
76.4 (55) 
2.8 (2) 
16.7 (12) 
4.2 (3) 
 
77.9 (120) 
7.8 (12) 
10.4 (16) 
3.9 (6) 
 
74 (271) 
5.5 (20) 
15.3 (56) 
5.2 (19) 
Diabetes (n) 22.1 (31) 18.1 (13) 12.3 (19) 17.2 (63) 
Metformin Use (n) 15.7 (22) 9.7 (7) 8.4 (13) 11.5 (42) 
Breast Cancer History (n) 2.9 (4) 23.6 (17) 15.6 (24) 12.3 (45) 
Table 5:  Participant Characteristics.  Characteristics are summarized by 
group – cancer, hyperplasia, and controls.  The hyperplasia group is younger 
with less diabetes and metformin use.  Ethnicity is similar across groups. 
As anticipated, the mean serum omentin levels were significantly higher in 
lean women (673 ng/mL) as compared to overweight (481 ng/mL) and obese 
women (475 ng/mL) with p<0.000.  This is demonstrated in figure 4.   
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Figure 4:  Mean Omentin Concentration by BMI Group.  Omentin  
  levels  were higher in lean patients as compared with overweight and  
  obese women.  
As seen in figure 5,  mean serum omentin levels were significantly lower in 
women with endometrial cancer as compared with matched controls (576 ng/mL 
vs 673 ng/mL, p=0.02).  Furthermore, among women with endometrial 
hyperplasia, the mean serum omentin concentration was significantly lower than 
matched controls (359 ng/mL vs 723 ng/mL, p<0.001).   
 
p<0.0001 
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 Figure 5:  Omentin Concentration in Cases versus Controls.  Women  
  with endometrial cancer and hyperplasia had significantly lower omentin  
  than their matched controls.   
When stratified by BMI, lean women with endometrial cancer had a 
statistically lower serum omentin level than lean controls.  However, there was no 
difference in omentin concentration between overweight and obese endometrial 
cancer patients and controls.  When women with hyperplasia were evaluated, 
there was a significantly lower serum omentin level in lean and obese cases 
when compared with controls.  However, there was no difference between 
overweight hyperplasia cases and controls (table 6). 
  
p=0.02 p<0.001 
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  Endometrial Cancer Controls p-value 
  
N 
Omentin 
(Mean) SD N 
Omentin 
(Mean) SD 
  
Total 74 575.76 229.47 74 673.77 324.87 0.0204 
BMI (kg/m2) 
       
< 25 21 667.73 241.60 21 954.06 317.46 <0.001 
25 to 30 15 474.31 153.79 15 593.30 250.35 0.177 
> 30 38 564.98 233.01 38 550.64 259.33 0.802 
  Endometrial 
Hyperplasia 
Controls p-value 
  
N 
Omentin 
(Mean) SD N 
Omentin 
(Mean) SD 
  
Total 74 359.57 199.64 74 723.32 449.80 <0.0001 
BMI (kg/m2) 
       
< 25 17 438.32 251.20 17 995.94 523.52 0.002 
25 to 30 16 354.79 212.33 16 652.42 575.61 0.068 
> 30 41 328.78 164.24 41 637.96 307.06 <0.001 
Table 6:  Mean Serum Omentin in Cases vs Controls Stratified by BMI. Only 
lean endometrial cancer patients have lower serum omentin than controls.  Lean 
and obese hyperplasia cases had lower omentin than controls. 
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Discussion 
 Prior studies have consistently shown an inverse relationship between 
omentin and obesity.  De Souza Batista and colleagues demonstrated that serum 
omentin levels are negatively correlated with BMI and waist circumference.[77]   
It has also been noted that serum omentin is decreased in patients with 
metabolic syndrome.  In a population of Japanese men, omentin levels were 
significantly lower in patients with large waist circumference, dyslipidemia, 
elevated blood pressure, and impaired glucose tolerance.[88]   Interestingly, 
weight loss has been shown to increase serum omentin levels and improve 
insulin sensitivity.[78] 
 The present study is consistent with other researchers, confirming that 
serum omentin concentration is inversely related to BMI.  Interestingly, there is 
not a strict negative correlation between omentin levels and BMI.  For example, 
while lean women were noted to have a significantly higher serum omentin than 
overweight and obese women, there was no difference in omentin levels 
between overweight and obese women.  The reasons for this are unclear.  
However, many factors others than BMI may influence omentin levels (i.e. waist 
circumference, amount of visceral vs peripheral fat, etc) and these confounders 
may account for the results in our study. 
There are currently no published studies evaluating the relationship 
between omentin and endometrial cancer.  In the present study, women with 
endometrial adenocarcinoma have decreased serum omentin levels when 
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compared with controls, as hypothesized.  However, when stratified by BMI, 
there was only a difference in omentin levels between lean cases and controls.  
Reasons for this finding are not clear.  However, it may be related to the 
relatively small numbers in each BMI group and other confounders that affect 
omentin levels.  
 The etiology of the relationship between omentin and endometrial cancer 
has not yet been investigated.   However, it is likely multifactorial and may be 
indirectly related to the inhibition of omentin’s anti-inflammatory effects.  Multiple 
studies in other disease processes have demonstrated omentin’s anti-
inflammatory properties.  In patients with juvenile arthritis, for example, omentin 
levels are lower among patients with active disease as compared with those with 
disease in remission.[89]  Patient’s with Crohn’s disease have also been found to 
have lower omentin levels, and it appears that these lower levels are important to 
disease activity.[90]  In vascular endothelial cells, omentin has been 
demonstrated to inhibit COX-2 expression by activating the AMPK and eNOS 
pathways, thereby decreasing inflammation.[82]  
Other adipokines may also be indirectly involved in the process of 
endometrial cancer development.  Leptin was the first adipokine to be discovered 
and is known to be associated with regulating appetite, weight, and 
metabolism.[91]  Elevated serum leptin levels have been associated with obesity 
and endometrial carcinoma.[92]  Another adipokine, adiponectin, has similar 
characteristics to omentin and has been shown to be inversely related to 
endometrial cancer.[59, 93]  An evaluation of patients with diabetes, impaired 
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glucose tolerance, and normal glucose tolerance noted a positive correlation 
between serum omentin levels and serum adiponectin levels.  Furthermore, 
serum adiponectin was an independent predictor of serum omentin levels.[76]  
The role of adipokines in the pathogenesis of endometrial cancer appears to be 
complex and has not been completely elucidated. 
How decreased levels of omentin directly affect endometrial cancer 
development has not yet been studied.  However, the mechanism may be 
extrapolated from work in other malignancies.  For example, there is evidence 
that omentin may activate apoptosis pathways.  In hepatocellular carcinoma cell 
lines, administration of omentin led to activation of the caspase-3 and JNK 
pathways.[94]  Other studies have suggested that omentin may play a role in 
tumor suppression.  In neuroblastoma, administration of intelectin-1 (omentin) led 
to suppression of cell growth, invasion, and metastasis.  This finding occurred 
both in vitro and in vivo.[95]  In ovarian cancer, unpublished data from our lab 
has demonstrated that omentin can aid with decreased cell proliferation, motility, 
and invasion potential.    
 The present study was the first to evaluate the relationship between 
omentin and complex atypical hyperplasia of the endometrium.  We found that 
women with endometrial hyperplasia possessed significantly lower serum 
omentin levels than controls.  When evaluated by BMI, lean and obese 
hyperplasia cases had lower omentin levels than controls.  As complex atypical 
hyperplasia represents a precancerous condition, these results suggest that 
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omentin may be related to the early changes in the endometrium that ultimately 
lead to the development of cancer. 
 Of interest, the mean serum level of omentin in women with endometrial 
hyperplasia was lower than that of women with endometrial cancer.  The reasons 
for this are unclear, as it would be expected that omentin levels in women with 
endometrial hyperplasia would be lower than that of controls, but higher than 
levels in women with endometrial cancer.  However, it should be noted that with 
a case-control design, the present study was not designed to directly compare 
omentin levels between women with endometrial cancer and women with 
hyperplasia.  Each group was matched to its own set of controls but not one 
another.  Therefore, it is difficult to assess if a true difference in omentin levels 
exists between the hyperplasia and cancer groups. 
 Our results further illuminate the intricate relationship between adipokines, 
obesity, and endometrial cancer.  While we have confirmed an inverse 
relationship between serum omentin levels and endometrial hyperplasia and 
carcinoma, the etiology for the lower omentin levels in these patients is unknown.  
It may be postulated that many endometrial cancer patients possess other risk 
factors associated with decreased omentin, such as obesity, diabetes, and 
PCOS.  In these cases, it is likely that comorbidities led to decreased serum 
omentin levels.  This, in turn, contributed to the development of endometrial 
cancer via absence of the tumor suppressor mechanisms of omentin.  However, 
presumably many women with decreased omentin due to other risk factors never 
develop endometrial cancer.  The etiology of this phenomenon should be 
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evaluated but may be related to downregulation of omentin expression by the 
cancer cells.  For example, unpublished work from our lab has noted that ovarian 
cancer leads to decreased omentin mRNA expression in the mesothelial cells.  
However, it should be remembered that endometrial cancer development is a 
complex process and unlikely to be soley dependent on low serum omentin 
levels.  Further research is warranted to investigate this.  
 The clinical implications of our study findings are currently only theoretical.  
For example, there is potential use of omentin as a biomarker for endometrial 
hyperplasia and its progression to cancer.  This may be especially true in lean 
women, as this was the only group noted to have significantly lower omentin 
levels in both hyperplasia and cancer cases when compared to controls.  Also, 
given that controls had higher serum omentin levels than cases, omentin may 
have utility in endometrial cancer prevention trials.  For example, it is known that 
serum omentin levels increase with weight loss and exercise.[78]  Additionally, in 
studies of PCOS, administration of metformin led to increased serum omentin 
levels.[80]  These findings provide for exciting possibilities for clinical trials if they 
hold true in women at high risk for endometrial cancer.  Furthermore, there is 
unpublished data from our lab demonstrating that serum omentin levels are 
inversely correlated with survival in ovarian cancer patients.  This finding is 
difficult to extrapolate to the low grade or early stage endometrial cancer 
population as these women typically have excellent overall survival at baseline.  
However, omentin may be a biomarker to predict survival or risk of recurrence in 
women with high grade or advanced stage endometrial cancer.  Additional 
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studies are warranted to explore this possibility.  Finally, given that administration 
of omentin to cancer cell lines leads to increased cell apoptosis and tumor 
suppression, it may be that omentin itself has a therapeutic benefit.  However, 
the role of omentin administration in preventing or reversing endometrial 
hyperplasia or cancer is unknown and needs to be further evaluated.   
 One of the main limitations of this study is its retrospective nature.  
Furthermore, serum samples were obtained from an institutional tumor bank and 
in some cases had been frozen for several years.  Though omentin is believed to 
be a very stable protein, determining omentin from fresh rather than frozen 
samples may provide more consistent results.  The relatively small number of 
samples that we evaluated may also limit this study, though our study was 
powered to detect a sufficient difference in omentin levels.  Finally, there is a 
wide number of clinical factors that may affect omentin levels other than obesity 
(diabetes, cardiovascular disease, arthritis, etc).  As it would be impossible to 
control for each of these, it is likely that our results are limited by these 
confounders. 
 Although it is clear that omentin is related to endometrial cancer and 
hyperplasia regardless of BMI, the etiology of this relationship is unknown.  As 
such, it is difficult to determine what clinical implications the association between 
endometrial cancer and omentin will provide.  Our results present exciting 
promise for omentin’s role in further understanding the relationship between 
obesity-related factors and endometrial cancer. 
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